GR-20263

Known as: GR 20263, GR20263 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1980-1982
012319801982

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1982
1982
The in vitro activities of moxalactam, GR 20263, and N-formimidoyl thienamycin were compared to those of cephalothin, cefazolin… (More)
Is this relevant?
1981
1981
The in-vitro activity of ceftazidime was determined against 586 clinical isolates of anaerobic bacteria by an agar-dilution… (More)
Is this relevant?
1981
1981
Ceftazidime was considerably more active than cefuroxime against 180 strains of resistant species of nosocomial gram-negative… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
1981
1981
The anti-pseudomonal activity of ceftazidime was determined by an agar-dilution technique against 92 strains of Pseudomonas… (More)
Is this relevant?
1981
1981
Ceftazidime was found to be highly active against routine hospital isolates of strains of Enterobacteriaceae such as Escherichia… (More)
Is this relevant?
1980
1980
GR 20263 is a new broad-spectrum injectable cephalosporin which is stable to most beta-lactamases. Its in vitro activities were… (More)
Is this relevant?
1980
1980
The in vitro activity of GR-20263, a new aminothiazolyl cephalosporin, was compared with the activities of other beta-lactam… (More)
Is this relevant?
1980
1980
The in vitro activity of GR 20263, a new cephalosporin, was compared primarily with the activities of moxalactam (LY 127935… (More)
  • table 2
Is this relevant?